

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

October 20, 2023

**Chordia named "Financing Deal of the Year."  
at the Citeline Pharma Intelligence Awards Japan 2023**

Kanagawa, Japan,

October 20, 2023 – Chordia Therapeutics Inc.(Chordia) has won the Financing Deal of the Year award at the Citeline Pharma Intelligence Awards Japan 2023. The Financing Deal of the Year category recognizes successful financing by a Japanese pharmaceutical or biotech company during the eligible period (January 1, 2022 - June 30, 2023). Chordia will continue its efforts to research and develop anti-cancer drugs through collaboration with universities, research institutes, and companies in the healthcare industry, with the aim of creating innovative new drugs.



**About the Citeline Pharma Intelligence Awards Japan 2023**

The awards are the Japanese version of the Scrip Awards, which have been running for 18 years in the UK and are known worldwide. They recognize excellence and innovation by Japanese pharmaceutical and biotech companies and highlight Japan's important role in the global healthcare industry. The purpose of the awards is to reflect together on the achievements of the previous year and to honor the companies and individuals' industry-wide who are paving the way for the future of the pharmaceutical industry.

Website: <https://www.citeline.com/ja-jp/awards/citelinepharmaintelligenceawards>

**About Chordia Therapeutics**

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



---

Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan and Phase1/2 clinical study in US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)